Valion Bio Inc.
VBIO | NASDAQ
$0.53
-$0.02 (-3.64%)
Nov 2, 2026, 1:41 PM ET · Market open
Fiscal Year Period Ending | FY 2026 Dec 31, 2025 | FY 2025 Dec 31, 2024 | FY 2024 Dec 31, 2023 | FY 2023 Dec 31, 2022 | FY 2022 Dec 31, 2021 | FY 2021 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 1.18M | 1.84M | 1.26M | 860K |
Cost of Revenue | n/a | 352K | 889K | 1.54M | 1.3M | 1.09M |
Gross Profit | n/a | -352K | 287K | 299K | -46K | -233K |
Operating Income | -7.9M | -4.42M | -8.25M | -10.1M | -5.63M | -3.32M |
Interest Income | 23K | 6K | 1K | 2K | n/a | n/a |
Pretax Income | -7.99M | -4.47M | -8.24M | -10.1M | -8.49M | -3.64M |
Net Income | -8.88M | -5.66M | -8.24M | -10.1M | -8.49M | -3.64M |
Selling & General & Admin | 4.77M | 2.75M | 6.88M | 8.67M | 4.72M | 2.32M |
Research & Development | 3.13M | 1.31M | 1.66M | 1.73M | 870K | 768K |
Other Expenses | n/a | -3K | n/a | n/a | n/a | n/a |
Operating Expenses | 7.9M | 4.06M | 8.53M | 10.4M | 5.59M | 3.09M |
Interest Expense | 146K | n/a | n/a | n/a | 1.82M | 423K |
Selling & Marketing Expenses | n/a | 1.19M | 2.13M | 2.79M | n/a | n/a |
Cost & Expenses | 7.9M | 4.42M | 9.42M | 11.94M | 6.89M | 4.18M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.16M | 287.37K | 46.65K | 5.69K | 2.05K | 5.45K |
Shares Outstanding (Diluted) | 1.16M | 287.37K | 46.65K | 5.69K | 2.05K | 5.45K |
EPS (Basic) | -7.84 | -19.68 | -176.80 | -1.77K | -4.13K | -667.69 |
EPS (Diluted) | -7.84 | -19.68 | -176.80 | -1.77K | -4.13K | -667.69 |
EBITDA | -7.84M | -4.06M | -8.06M | -9.92M | -5.61M | -3.31M |
EBIT | -7.85M | -4.42M | -8.25M | -10.1M | -5.63M | -3.32M |
Depreciation & Amortization | 5K | 352K | 182K | 174K | 24K | 8K |
Add to Watchlist
Select watchlists to add or remove VBIO